We Are Main Street

Liver Testing Pathways Move Toward Implementation

Diagnostic and drug companies face shifting reimbursement and referral pathways as a national roadmap for non-invasive liver testing takes shape.

Updated on Nov. 5, 2026 in Industry

Liver Testing Pathways Move Toward Implementation

Global Liver Institute convened the Beyond the Biopsy National Implementation Forum in Denver on November 4, bringing together patients, clinical experts, researchers, diagnostic companies, and pharmaceutical companies to set priorities for non-invasive liver disease assessment. The group will use the discussion to draft a National Implementation Roadmap, relevant to healthcare operators in diagnostics, clinical services, and drug development.

Why it matters

An estimated 1 in 4 adults worldwide lives with metabolic dysfunction-associated steatotic liver disease, which can progress to steatohepatitis, yet many at-risk people are never screened. Stakeholders are working to close gaps in identification, referral, reimbursement, and follow-up, which shapes demand and payment pathways for non-invasive testing.

An estimated 1 in 4 adults worldwide lives with metabolic dysfunction-associated steatotic liver disease (MASLD), a figure the Forum used to frame the scale of the problem. The source does not provide a comparator or a measured screening rate for at-risk individuals.

The players

Global Liver Institute

A liver disease research and education organization that convened the Forum and will develop the draft National Implementation Roadmap.

GENFIT

A French biopharmaceutical company focused on liver disease therapies, whose Chief Executive Officer Pascal Prigent spoke at the Forum.

The details

The Forum was convened to establish patient-centered priorities that will inform a draft National Implementation Roadmap for non-invasive liver assessment. Discussions focused on strengthening clinical workflows and clarifying who is responsible for interpreting test results and for follow-up care. Gaps examined included patient identification, diagnostic assessment, referral pathways, access, reimbursement, and ongoing care. The Forum built on Global Liver Institute's 2025 Non-Invasive Testing Summit.

Timeline

  1. November 4, 2026: Beyond the Biopsy National Implementation Forum held in Denver, ahead of The Liver Meeting.

  2. 2025: Global Liver Institute's Non-Invasive Testing Summit, which the Forum built upon.

Market Landscape

The Forum follows Global Liver Institute's 2025 Non-Invasive Testing Summit, shifting the conversation from scientific validation of non-invasive tests toward implementation. Participation by diagnostic companies and pharmaceutical companies alongside clinicians signals that testing pathways are an industry-wide concern.

Healthcare operators in diagnostics, clinical practice, and drug development should watch how the draft roadmap assigns responsibility for interpreting non-invasive test results and for follow-up care. Reimbursement and referral pathways discussed at the Forum are the operational lines most likely to shape where testing revenue and clinical workload land.

The takeaway

The Forum's emphasis on reimbursement and referral gaps means implementation, not testing technology alone, will determine adoption. Operators should monitor the draft National Implementation Roadmap for the specific responsibilities and payment mechanisms it proposes.

What happens next

Global Liver Institute will develop a draft National Implementation Roadmap outlining key implementation barriers and proposed actions, though the source gives no date for its release.

Further reading

For broader context on how diagnostic testing pathways are organized, see Healthcare coverage in Denver.